⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELC News
Celcuity Inc. Common Stock
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
globenewswire.com
CELC
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
globenewswire.com
CELC
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight
globenewswire.com
CRSP
TMO
EDIT
LGL
SANG
PRGS
CELC
REGN
ILMN
MYGN
BIIB
DHR
ROST
QGEN
DGX
ABT
MRK
PACB
AZTA
Form 8-K
sec.gov
CELC
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
globenewswire.com
CELC
Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight
globenewswire.com
CRSP
TMO
RGEN
ILMN
MYGN
DHR
QGEN
DGX
PACB
AMGN
AGNC
CELC
PERI
MRK
MTX
AZTA
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Form 8-K
sec.gov
CELC
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
CELC
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
globenewswire.com
CELC